Addex Says Phase 2 Feasibility Study Of Dipraglurant For Blepharospasm Did Not Meet All Goals

Addex Therapeutics Ltd (ADXN) on Friday said Phase 2a feasibility study of dipraglurant in patients with blepharospasm did not meet all of its goals.

Blepharospasm is characterized by involuntary contractions of the eyelid muscles resulting in visual disturbance or functional blindness.

The primary objective of the Phase 2a feasibility study that enrolled 15 patients, was to evaluate the safety and tolerability of dipraglurant in patients with blepharospasm.

Addex said the study was inconclusive and did not meet all of its objectives.

Another Phase 2B/3 study of dipraglurant for the treatment of Parkinson's disease levodopa induced dyskinesia remains on track to report data in the first half of 2023, the company added.

Dipraglurant is a metabotropic glutamate receptor subtype 5 negative allosteric modulator, or mGlu5 NAM, the company said.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Longmont Colorado -based Royal Crest Dairy is recalling 2% Chocolate Milk citing the potential to be contaminated with undeclared egg, a known allergen, the U.S. Food and Drug Administration said. The recall involves Farmer's 2% Reduced Fat Chocolate Milk Pints with the code date of AUG-22. ANI Pharmaceuticals, Inc. (ANIP) Monday announced a wider loss for the second quarter, despite a 52 percent surge in revenues. For the full year 2022, the company reiterated the adjusted earnings per share range, revenue guidance and raised Cortrophin revenue outlook. The company reported a quarterly... Shares of BioNTech SE were losing around 4 percent in the morning trading in Germany and around 5 percent in the pre-market activity on Nasdaq after the German Covid-19 vaccine maker reported sharp drop in profit and revenues for the second quarter. However, the company recorded strong growth in first-half results. Further, the company maintained BioNTech COVID-19 vaccine revenue guidance
Follow RTT